<!-- a B16/PDGF-BB clone MWx10-3 PDGF-BB 50 ng/ml B16/mock clone B16/PDGF-BB clone PDGF-BB 0.1 ng/ml PDGF-BB 0.5 ng/ml PDGF-BB 5 ng/ml PBS PBS 200- IB:pTyr 200- IB:PDGFRβ  -->
![](https://web-api.textin.com/ocr_image/external/c4d19f6427c43e5c.jpg)

<!-- b 107 Jedunu 1e0 106 105 104 0 2 4 6 Time(days) 8  -->
![](https://web-api.textin.com/ocr_image/external/8d7b64576b78a0b7.jpg)

<!-- C vehicle(n=7) (2트)eunioA JounL 500 -ST1571(n=6) PTK787(n=5) 400 -PTK787/STI571(n=7) 300 200 §§ 100 0 0 2 4 6 8 Time(days) 10 12 14  -->
![](https://web-api.textin.com/ocr_image/external/42707c6f9febd374.jpg)

<!-- vehicle(n=8) (2Hu)aunloA JounL STI571(n=8) 500 PTK787(n=7) 400 -PTK787/STI571(n=9) 300 200 100 *§# 0 0 2 4 6 Time(days) 8 10  -->
![](https://web-api.textin.com/ocr_image/external/3616163fb2927103.jpg)

<!-- e M W \times 1 0 ^ { - 3 } C Veh STI PTK PTK STI 100 STI 200 250 1B:pTyr 150- 250- 150- IB:PDGFRβ 1 \frac { 1 . 3 } { 4 5 } 0.6 60.2 1.4 0.9 \underline { 0 . 1 } 0 . 6 \underline { 0 . 1 0 . 1 } Relative phosph. 1.15 0.40 1.15 0.35 0.10 Mean relative phosph.  -->
![](https://web-api.textin.com/ocr_image/external/7c6dd2b8298d3c73.jpg)

FIGURE 1- Combination of VEGFR and PDGFR tyrosine kinase inhibitors inhibits B16 melanoma tumor growth in vivo. (a) Subconfluent cultures of PAE/PDGFRβ cells were stimulated with conditioned media from B16/mock or B16/PDGF-BB cells for 1 hr on ice (left panels).Alternatively,PAE/PDGFRβ cells were incubated for 5 min at 37°C with conditioned medium or increasing amounts of PDGF-BB (right pan-els). PDGFRβ phosphorylation was analyzed by PDGFRβ and phospho-tyrosine (pTyr) immunoblotting of wheat germ agglutinin adsorbed fractions of cell lysates. (b) B16/PDGF-BB cells were seeded in 12-well plates and cultured in the presence of vehicle fractions of cell lysates. (b) B16/PDGF-BB cells were seeded in 12-well plates and cultured in the presence of vehicle (),3 μM STI571 () ( ),1μM PTK787 (A)or 3 μM STI571 and 1 μM PTK787(·).B16/mock (c)or B16/PDGF-BB (d) cells were inoculated subcutaneously to C57B16/J mice. When the tumor volume reached 20 mm3, mice received either p.o. gavage of vehicle (),100 mg/kg/day STI571 ( ),25 mg/kg/day PTK787(A)or 100 mg/kg/day STI571 and 25 mg/kg/day PTK787 (O).Treatment was given for 13 days for mice bearing B16/mock tumors (c)and 8 days for mice bearing B16/PDGF-BB tumors (d). Tumor volumes, determined by palpation were followed over time. Results are presented as mean and S.E.M. Statistical significance was evaluated using a one-way ANOVA followed by post hoc analysis applying the Duncan adjust-ment. Significance is shown for the last day of treatment:*,p&lt;0.05 compared to vehicle treatment;§,p &lt;0.05 compared to PTK787 treat-ment;#,p&lt;0.05 compared to STI571 treatment. (e) Sis-NIH3T3 tumors treated with vehicle (lanes 2 and 3), a combination of PTK787/STI571(25 mg/100 mg/kg/day; lanes 4 and 5), PTK787 (25 mg/kg/day, lanes 6 and 7), STI571 (100 mg/kg/day, lanes 8 and 9) or STI571(200 mg/kg/day,lanes 10 and 11). PDGFRβ was immunoprecipitated from 15 mg tumor lysate, and receptor phosphorylation was analyzed by PDGFRβand phospho-tyrosine (pTyr) immunoblotting. Rabbit IgG recognizing PTEN was used for immunoprecipitation as a negative control (lane 1).The ratio between the densitometric analysis of the phosphotyrosine band and the upper, mature PDGFRβ band were compared to the first vehi-cle-treated tumor to obtain the relative receptor phosphorylation.

## Results

In vitro characterization of a B16F10 melanoma clone which produces PDGF-BB

A B16 melanoma cell line producing PDGF-BB (B16/PDGF-BB)was previously established.26 This cell line was used to iso-late a clone with robust PDGF-BB production that was selected for further experiments. As shown in Figure 1a (left panels), con-ditioned medium from the selected B16/PDGF-BB clone,but not from a mock-transfected clone (B16/mock), induced strong PDGFRβ phosphorylation in porcine aortic endothelial cells

transfected with the PDGFRβ (PAE/PDGFRβ),indicating pro-duction of a large amount of PDGF-BB. The amount of PDGF-BB released into the conditioned medium was estimated by incu-bating PAE/PDGFRβ cells with either conditioned medium or increasing amounts of PDGF-BB. After 2 days, the B16/PDGF-BB cells had released an amount of PDGF into the medium that was in excess of 0.5 ng/ml PDGF-BB (Fig. 1a, right panels). It should be noted that PDGF-BB sticks to both cells and plastic, so this amount is likely to represent underestimation of the produc-tion of PDGF-BB.

